Key result
Patients with acute coronary syndromes and baseline BNP levels > 80 pg/ml had a significantly higher risk of mortality within 30 days compared to those with BNP ≤ 80 pg/ml (17.8% vs 1.39%, OR 15.4, p=0.002).
Why the study?
The study was designed to evaluate the prognostic value of B-type natriuretic peptide (BNP) across the entire spectrum of acute coronary syndromes.
Does a single baseline measurement of BNP predict short-term morbidity and mortality in patients across the spectrum of acute coronary syndromes?
Cross-Sectional (n=100)
No
Does a single baseline measurement of BNP predict short-term morbidity and mortality in patients across the spectrum of acute coronary syndromes?
Odds Ratio: 15.4
Absolute Event Rate: 17.8% vs 1.39%
p-value: p=0.002
A single measurement of BNP between 24-96 hours after ischemic symptom onset provides powerful prognostic information for 30-day mortality and morbidity across the spectrum of acute coronary syndromes.
May support BNP for short-term risk stratification in ACS; hypothesis-generating and should not yet change practice.
Objectives: This study was designed to evaluate the prognostic value of B-type natriuretic peptide (BNP) in patients across the entire spectrum of acute coronary syndromes (ACS). Method: We measured BNP levels at baseline in 100 consecutive patients between 24-96 hours after the onset of ischemic symptoms in patients of acute coronary syndromes. We did comparison between BNP levels and established prognostic markers Trop-T to determine short term morbidity and mortality. Results: Patients with baseline BNP levels (> 80pg/ml, n=28) were at higher risk of new or progressive congestive heart failure (CHF) [17.8% vs. 1.39%, P = 0.002), new or recurrent myocardial infarction [17.8% vs. 2.8, P = 0.008) and death [17.8% vs. 1.39%, P= 0.002) within a period of 30 days. The mortality within 30 days in patients with BNP > 80pg/ml was 17.9% (P=0.002)compared to 5.7%(P=0.718) in patients with positive Trop-T (> 0.1ng/ml). Conclusion: A single measurement of BNP obtained between 24-96 hours after the onset of ischemic symptoms provides predictive information for use in risk stratifications across the spectrum of acute coronary syndromes. Cardiac neurohormonal activation may be a unifying feature among patients at high risk for death after acute coronary syndromes. BNP levels should be measured in all patients of Acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2020) conducted a cross-sectional in Acute Coronary Syndromes (ACS) (n=100). Baseline BNP levels > 80 pg/ml vs. Baseline BNP levels ≤ 80 pg/ml was evaluated on Mortality within 30 days (OR 15.4, p=0.002). Patients with acute coronary syndromes and baseline BNP levels > 80 pg/ml had a significantly higher risk of mortality within 30 days compared to those with BNP ≤ 80 pg/ml (17.8% vs 1.39%, OR 15.4, p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: